Company
Headquarters: Seattle, WA, United States
Employees: 85
CEO: Dr. Mitchell H. Gold M.D.
$1.03 Billion
USD as of Jan. 1, 2024
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | CHF782,000 |
| EBITDA | CHF0 |
| Gross Profit TTM | CHF782,000 |
| Profit Margin | -141.56% |
| Operating Margin | 59.59% |
| Quarterly Revenue Growth | -51.00% |
Alpine Immune Sciences, Inc. has the following listings and related stock indices.
Stock: NASDAQ: ALPN wb_incandescent
Stock: FSX: 34LA wb_incandescent